Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

A Blauvelt,M Lebwohl,F Fierens,F Brock,Rb Warren,K Reich,V Ciaravino

doi:10.25251/skin.5.supp.19

Abstract

Abstract not available.

Highlights

Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-tumor necrosis factor agent that has shown durable clinical improvements over 144 weeks of treatment in patients with moderate to severe plaque psoriasis (PSO).1
We present Dermatology Life Quality Index (DLQI) results over 144 weeks of CZP treatment to evaluate the impact of CZP across different DLQI subdomains and to expand upon DLQI remission rates (DLQI 0/1) previously reported
Data were pooled from CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272), phase 3 trials in adults with moderate to severe PSO; detailed study designs have been described previously (Figure 1)

Summary

Introduction

Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-tumor necrosis factor agent that has shown durable clinical improvements over 144 weeks of treatment in patients with moderate to severe plaque psoriasis (PSO).. PSO can negatively impact health-related quality of life (HRQoL), with links to pain and discomfort, social stigmatization, and psychological distress.. It is important to understand whether clinical responses translate into long-term improvements in HRQoL. We present Dermatology Life Quality Index (DLQI) results over 144 weeks of CZP treatment to evaluate the impact of CZP across different DLQI subdomains and to expand upon DLQI remission rates (DLQI 0/1) previously reported.

Methods

Results

Conclusion

CZP 400 mg Q2W CZP 200 mg Q2W

Conclusions